News
NUVB-WS
0.0051
+24.39%
0.0010
Analyst Maintains Buy Rating on Taletrectinib Developer, Reaffirming $17 12-Month Price Target on Strengthening ROS1+ NSCLC Outlook
TipRanks · 1d ago
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers
PR Newswire · 2d ago
Weekly Report: what happened at NUVB last week (0420-0424)?
Weekly Report · 2d ago
Is It Time To Reassess Nuvation Bio (NUVB) After Its Recent Share Price Surge?
Simply Wall St · 6d ago
Analysts Are Bullish on Top Healthcare Stocks: Nuvation Bio (NUVB), Spyre Therapeutics (SYRE)
TipRanks · 04/22 14:00
Nuvation Bio Data And Japan Rights Add Weight To Undervalued Story
Simply Wall St · 04/22 11:20
Nuvation Bio reports results from TRUST-I and TRUST-II trials for IBTROZI
TipRanks · 04/21 22:05
Nuvation Bio Reveals IBTROZI Showed Highly Durable Responses in Longer-Term Follow-Up Data From Pivotal Studies Presented At AACR 2026; IBTROZI Also Demonstrated A High Overall Response Rate In TKI-Naïve Patients At 89.8%; Preclinical Data Presented At AACR Showed Taletrectinib's Potential For Suppressing TrkB-mediated Lung Cancer Cell Migration
Benzinga · 04/21 22:04
Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026
PR Newswire · 04/21 22:00
Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026
PR Newswire · 04/20 20:05
Weekly Report: what happened at NUVB last week (0413-0417)?
Weekly Report · 04/20 09:41
A Look At Nuvation Bio’s Valuation As Ibtrozi Uptake And Q1 Earnings Expectations Gain Attention
Simply Wall St · 04/18 13:07
Nuvation Bio Price Target Maintained With a $11.00/Share by Wedbush
Dow Jones · 04/16 13:41
Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target
Benzinga · 04/16 13:31
Nuvation Bio (NUVB) Gets a Buy from Wedbush
TipRanks · 04/16 12:36
Weekly Report: what happened at NUVB last week (0406-0410)?
Weekly Report · 04/13 09:42
Insider Sells 200K Shares of Biotech Company Nuvation Bio (NUVB)
The Motley Fool · 04/13 04:24
How Investors May Respond To Nuvation Bio (NUVB) EMA Review Of Taletrectinib Milestone Opportunity
Simply Wall St · 04/10 22:26
Analysts Are Bullish on These Healthcare Stocks: GE Healthcare Technologies Inc (GEHC), Nuvation Bio (NUVB)
TipRanks · 04/08 11:31
RBC Capital Sticks to Their Buy Rating for Nuvation Bio (NUVB)
TipRanks · 04/08 01:50
More
Webull provides a variety of real-time NUVB-WS stock news. You can receive the latest news about Nuvation Bio Inc through multiple platforms. This information may help you make smarter investment decisions.
About NUVB-WS
Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.